Clinical trials: Antiviral Treatment
Influenza
Severe Influenza Trial of ARbidol
This is a multicenter, randomised, double-blind, controlled study to assess the efficacy and safety of arbidol plus oseltamivir, compared with oseltamivir alone in approximately 200 hospitalized adults and adolescent patients…
- Trial name
- STAR (NCT03787459)
- Testing
- Arbidol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Capital Medical University
Hepatitis C Virus
Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease
The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.
- Trial name
- PEG-IFN-SA (NCT01605513)
- Testing
- interferon
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Hospital of Jilin University
Influenza, Human
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu.
- Trial name
- ZORO (NCT01231620)
- Testing
- Zanamivir, Oseltamivir
- Where
- 170 sites in United States, Australia and 26 more
- Volunteers
- 626 people
- Sponsor
- GlaxoSmithKline
HIV
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)
- Trial name
- NCT00634959
- Testing
- Maraviroc (UK-427,857)
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- ViiV Healthcare
Hepatitis C
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
Neuropsychiatric adverse effects of direct acting antiviral drugs, especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C , genotype four (the predominant…
- Trial name
- NCT03268317
- Volunteers
- 100 people
- Sponsor
- Assiut University
HIV Infections
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy…
- Trial name
- NCT06214052
- Testing
- VH4524184, Antiretroviral therapy
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 22 people
- Sponsor
- ViiV Healthcare
HIV Infections, Chickenpox
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
- Trial name
- NCT00002315
- Testing
- Netivudine, Acyclovir
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Glaxo Wellcome
Chronic Hepatitis B
The Establishment of Korean Hepatitis B Patients Cohort
According to the World Health Organization about 1,400,000 deaths reported annually, are related to chronic liver disease. Chronic liver disease is very prevalent in South Korea, placing a large economic burden nationwide.
- Trial name
- NCT04139850
- Testing
- Discontinuation of antiviral treatment in chronic hepatitis B cohort patients
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Yonsei University
HIV Infections
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection.
- Trial name
- NCT07202546
- Testing
- VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 186 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis C
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic…
- Trial name
- NCT00332176
- Testing
- Celgosivir, Peginterferon alfa 2b + ribavirin
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- BioWest Therapeutics Inc
HIV Infections
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine).
- Trial name
- NCT00002240
- Testing
- Atazanavir, Nelfinavir mesylate, Stavudine
- Where
- 17 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
Australia Antigen Positive, Hepatitis B
Optimization of Antiviral Therapy of Chronic HBV Infection
Along with the improvement of the accuracy of detection of HBV serological markers, the optimization of antiviral therapy for patients with chronic hepatitis B (CHB) infection becomes feasible.
- Conditions
- Australia Antigen Positive, Hepatitis B, Adverse Effects
- Trial name
- NCT01623778
- Testing
- Interferon Alfa-2a add on ADV
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Changhai Hospital
Renal Failure Chronic, Hepatitis C
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
Open label single center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT03093740
- Testing
- Zepatier, Zepatier plus Sofosbuvir
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Hepatitis C Infection, HIV Infection
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
The purpose of this study was to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks for treatment of acute hepatitis C (HCV), with or without HIV-1 coinfection.
- Trial name
- PURGE-C (NCT04042740)
- Testing
- Glecaprevir/Pibrentasvir (G/P)
- Where
- 12 sites in United States, Brazil
- Volunteers
- 45 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Anemia, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa versus placebo for the treatment of anemia in AIDS (Acquired Immunodeficiency Syndrome) patients with anemia that is a result of this disease…
- Trial name
- NCT00270010
- Testing
- epoetin alfa
- Volunteers
- 72 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV Infections
A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex
To evaluate the safety, minimum effective dose (MED), pharmacokinetics and efficacy of orally administered 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) in patients with AIDS or AIDS related complex (ARC).
- Trial name
- NCT00000988
- Testing
- Stavudine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Virus Infection, Response to Therapy of, Drug Use
HCV Reinfection After DAA Therapy in PWID in Belgium
The primary aim of this study is to calculate the incidence of HCV reinfection after successful DAA treatment among people who have recently injected drugs.
- Trial name
- REINF_HCV (NCT04251572)
- Testing
- Blood sampling, questionaires
- Where
- 10 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Hasselt University
Hepatitis C, Chronic
Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
The main purpose of the study is to determine the antiviral efficacy and evaluate the safety and tolerability of sofosbuvir/ velpatasvir (SOF/VEL) and sofosbuvir/ velpatasvir/ voxilaprevir (SOF/VEL/VOX) used to treat individuals…
- Trial name
- SHARED3 (NCT03888729)
- Testing
- sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir
- Where
- Rwanda
- Volunteers
- 100 people
- Sponsor
- Partners in Health
Hepatitis B Virus (HBV), Lung Transplant Recipient
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
- Trial name
- CLEAR-HBV (NCT07189377)
- Testing
- Entecavir, HBIG, EVLP UV Light Treatment
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
HIV Infections
A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin
This study involves GLQ223 administration to patients who have not previously been exposed to it, but who have received at least 9 months of zidovudine therapy.
- Trial name
- NCT00001989
- Testing
- Trichosanthin, Zidovudine
- Where
- 8 sites in United States
- Sponsor
- Genelabs Technologies